Wedbush keeps a Neutral rating on Apellis shares after the FDA issued a revised label Syfovre in geographic atrophy following its analysis/review of recent retinal vasculitis events. The FDA’s move was largely anticipated given the focus on the retinal vasculitis events and the label incorporates new language in the warnings/precautions section, the analyst tells investors in a research note. The key to unlocking additional Apellis value remains tied to re-accelerating Syfovre commercial uptake and securing ex-U.S. Syfovre approvals, Wedbush contends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis director Dunlop sells 24,000 common shares
- Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
- Apellis price target raised to $49 from $42 at Mizuho
- Goldman Sachs Says These 2 Healthcare Stocks Look Attractive — Here’s What Makes Them Each a ‘Buy’ Right Now
- Tesla initiated, Kellanova upgraded: Wall Street’s top analyst calls